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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comand frequencies simulating various physiological conditions at the start and after 100
million cycles.
Results: Analysis was performed with transapical Jenavalve prostheses (27mm)
implanted in circular annuli (n¼3) or annuli with 0.84 eccentricity (n¼3). Hydrody-
namic testing showed no signiﬁcant difference in valve performance with regard to the
average regurgitation volume under both conditions at the start [circular: 4.69%
0.20%; oval: 4.81%2.05% of total stroke volume; p¼n.s.] Interestingly after a
durability test of 100 million cycles hydrodynamic testing showed a slightly reduced
average regurgitation volume in the oval annulus [circular: 5.53%0.19%; oval:
3.59%0.39% of total stroke volume; p¼n.s.]. Macroscopic analysis and histology
revealed no difference between valve leaﬂets of the two groups.
Conclusions: This is the ﬁrst experimental in vitro durability study demonstrating no
signiﬁcant difference in valve performance and regurgitation volume for a percuta-
neous valve implanted in an eccentric annulus.
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Background: The aim of this study is to compare the clinical outcomes after trans-
catheter aortic valve implantation (TAVI) with the Edwards SAPIEN/SAPIEN XT
transcatheter heart valve (ESV) versus the Medtronic CoreValve (MCV) in Asian
countries.
Methods: The data from databases of 3 Asian centers were pooled and analyzed.
Study objectives were Valve Academic Research Consortium outcomes at 30 days
and 1 year. In total, 185 patients were included: 86 (46.5%) treated with the ESV and
99 (53.5%) with the MCV.
Results: Previous PCI, previous CABG and peripheral artery disease were more
frequent in ESV group but aortic annulus area and perimeter measured by MDCT
were larger in MCV group. There were no differences in baseline echocardiographic
ﬁndings and calciﬁcation grade. Device success occurred in 78 of 86 patients
(90.7%) in ESV group and 74 of 99 (74.7%) patients in MCV group (relative risk
[RR],1.21; 95% conﬁdence interval [CI]: 1.40 to 7.75;p¼ 0.005).This was attributed
to a signiﬁcantly lower frequency of residual more-than-mild aortic regurgitation
(7.2% vs. 16.0%; RR, 0.45; 95% CI 0.90 to 6.61; p ¼ 0.07) and the less frequent
need for implanting more than 1 valve (0% vs. 10.1%;p ¼ 0.002). All-cause
mortality at 30 days was 4.7% in ESV group and 2.0% in MCV group (RR, 2.35;
95% CI, 0.42 to 13.33; p ¼ 0.42). Stroke, bleeding and vascular complications were
not signiﬁcantly different, and the combined safety end point occurred in 14.0% in
ESV group and 10.1% in MCV group (RR, 1.39; 95% CI, 0.59 to 3.53; p ¼ 0.42).
Placement of a new permanent pacemaker was less frequent in the ESV group
(1.2% vs. 22.2%, p< 0.001). At 1 year, there were no difference in all-cause
mortality (8.6% vs. 8.5%; hazard ratio [HR], 0.77; 95% CI, 0.28 to 2.23; p ¼ 0.61)
and combined efﬁcacy endpoint (15.1% vs. 22.2%; RR, 0.68; 95% CI, 0.29 to 1.33;
p ¼ 0.22).
Conclusions: Among patients with aortic stenosis undergoing TAVI in Asian coun-
tries, the use of ESV resulted in a greater rate of device success than use of MCV,
however combined safety endpoint at 30 days, and all-cause mortality and combined
efﬁcacy endpoint at 1 year were similar between 2 groups.
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Background: Although transcatheter aortic valve implantation (TAVI) has widened
the indication for the treatment of aortic valve stenosis (AS), there is still a group of
patients considered ‘extremely high-risk’, including those with severely decom-
pensated heart failure. The aim of this study is to evaluate the early results of TAVI
under cardiopulmonary bypass support (CPS) (on-pump TAVI) in patients with
severely decompensated heart failure.
Methods: Among 157 cases from October 2009 through April 2014, twelve patients
(7.6%) were treated by on-pump TAVI using SAPIEN/SAPIEN XT. Mean age was
816 years and left ventricular ejection fraction (LVEF) was signiﬁcantly low
(337). Ten patients (83%) were dependent on catecholamine support and one
patient (8.3%) was required CPS preoperatively. Mean preoperative BNP was
signiﬁcantly high (1562 pg/ml). EuroSCORE was 6225% and STS score was
2723%.B220 JACC Vol 64/11/Suppl B j SepResults: Urgent procedure was required in three cases (25%). Transapical procedure
was preformed in three cases (25%). Procedural success was 100% and CPS was
removed in operating room in all patients (pump time, median: 13 minutes). One
patient was died from coronary event 3 postoperative day. There were no thrombo-
embolic and neurologic complications. Ten patients (83%) were discharged to home.
LVEF at 1-month was signiﬁcantly improved (49%, p< .05). The 30-day mortality
was 8.3% and survival at 6- and 12-months were 91% and 78%, respectively (mean
follow-up period, 332277 days).
Conclusions: We achieved satisfactory early and short-term outcomes of on-pump
TAVI. On-pump TAVI may become the standard therapy to treat aortic valve stenosis
in the presence of severely decompensated heart failure.
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Background: Cerebrovascular embolization is frequent during Transcatheter Aortic
Valve Implantation (TAVI). The aim of this study was to identify variables associated
with tissue embolization during TAVI.
Methods: A total of 82 patients underwent TAVI with a dual ﬁlter– based embolic
protection device (Montage Dual Filter System, Claret Medical, Inc) deployed in the
brachiocephalic trunk and left common carotid artery. Both balloon expandable and
self-expanding transcatheter heart valves (THV) were used. After TAVI the ﬁlters
were retrieved and sent for histopathologic analysis.
Results: Overall, debris was captured in 86% of patients. Captured material varied in
size from 0.1 to 9.0 mm. Thrombotic material was found in 74% of patients and tissue-
derived debris in 63%. Tissue-derived debris was found more often with balloon
expandable THV (79% vs. 56%, p ¼ 0.05). The dislodged material corresponded best
with dislodged tissue from the native aortic valve leaﬂets, aortic wall or left ventricular
myocardium. Balloon-expandable THV (adjusted OR: 12.100; 95% CI 1.925-76.040,
p ¼ 0.008) and cover index (adjusted OR: 1.151, 95% CI 1.015-1.307, p ¼ 0.029)
were independent predictors for tissue embolization by multivariable logistic regres-
sion analysis.
Conclusions: Debris is captured with ﬁlter-based embolic protection in the vast
majority of patients undergoing TAVI. Tissue derived material is found in 63% of
cases and is correlated with the use of balloon expandable systems and more
oversizing.
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Background: Trancatheter Aortic Valve Implantation (TAVI) is an option to treat
pure severe aortic regurgitation (PSAR) in patients at high surgical risk. We hereby
report the 3-year follow-up (3-y FU) of patiens with inoperable PSAR treated in our
Institute using Medtronic CoreValve prosthesis.
Methods: Aortic valve sizing was assessed on 3 dimensional-CT scan considering
perimeter, area, major and minor orthogonal annular diameter. An oversizing pros-
thesis with respect of annular perimeter was used. We developed a size table (see
below) to choose the right valve dimension. Sixteen pts with PSAR underwent TAVI
with CoreValve prosthesis (mean age 84+2,6; mean L-Euroscore 33%)Results: A procedural success has been reached using a single valve in 13 pts. In
these pts we observed an improved functional capacity and no death at a 3-y FU. In
one case a second valve deployment (CoreValve 29 mm in Core-Valve 31 mm) was
necessary to reduce the peri-leak severe aortic regurgitation obtaining a ﬁnal mod-
erate grade of aortic regurgitation. In this case we observed a worsening of NYHA
class after 1-y FU and frequent re-hospitalizations for congestive heart failure at 3-y
FU. In 2 cases conversion to emergency open surgery and aortic valve replacement
was required due to residual severe aortic regurgitation despite a second valve
deployment. These 2 pts died 1 year after the procedure (one from infective endo-
carditis and one from acute pulmonary edema). A new permanent PM implantation
was necessary in 7 pts.tember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
